Akers Biosciences, Inc. announced that its proposed merger partner MyMD Pharmaceuticals, Inc. has completed the formation of its Scientific Advisory Board. The board will be chaired by Katharine Whartenby, Ph.D., associate professor at the Johns Hopkins University School of Medicine Department of Neurology, Department of Oncology and in Cellular and Molecular Medicine. Members of the MyMD Scientific Advisory Board include: Katharine Whartenby as chairman. Jeremy Walston, Scott Freeman, Ryan Vandrey, Alison O’Mahony, Anupama Kumar.